{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:05:34Z","timestamp":1772197534569,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,30]]},"DOI":"10.7759\/cureus.91301","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T18:52:06Z","timestamp":1756579926000},"source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Statin Therapy on Liver Enzymes and Fibrosis Progression in Patients With Coexisting Cardiovascular Disease and Non-alcoholic Fatty Liver Disease (NAFLD)"],"prefix":"10.7759","author":[{"given":"Tehniyat","family":"Khadija","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zunaira","family":"Rizwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Joel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz Muhammad Faizan","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Abdul Razzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Tayyab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mavish","family":"Arif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.03.003","article-title":"Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"18","author":"Ho A","year":"2024","unstructured":"Ho A, Kiener T, Nguyen QN, Le QA. Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD). J Clin Lipidol. 2024, 18:e501-8. 10.1016\/j.jacl.2024.03.003","journal-title":"J Clin Lipidol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023, 79:1542-56. 10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song SJ","year":"2024","unstructured":"Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition?. J Hepatol. 2024, 80:e54-6. 10.1016\/j.jhep.2023.07.021","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5493\/wjem.v14.i4.98543","article-title":"Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","volume":"14","author":"Tarar ZI","year":"2024","unstructured":"Tarar ZI, Farooq U, Inayat F, et al.. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis. World J Exp Med. 2024, 14:98543. 10.5493\/wjem.v14.i4.98543","journal-title":"World J Exp Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i11.1307","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice","volume":"25","author":"Zhou JH","year":"2019","unstructured":"Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice.  World J Gastroenterol. 2019, 25:1307-26. 10.3748\/wjg.v25.i11.1307","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al.. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019, 71:793-801. 10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam M","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, et al.. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020, 14:889-919. 10.1007\/s12072-020-10094-2","journal-title":"Hepatol Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella ME","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024, 29:101133. 10.1016\/j.aohep.2023.101133","journal-title":"Ann Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/pr9010135","article-title":"Non-alcoholic fatty liver disease: from pathogenesis to clinical impact","volume":"9","author":"Caturano A","year":"2021","unstructured":"Caturano A, Acierno C, Nevola R, . Non-alcoholic fatty liver disease: from pathogenesis to clinical impact. Processes. 2021, 9:135. 10.3390\/pr9010135","journal-title":"Processes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy G","year":"2020","unstructured":"Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun. 2020, 4:478-92. 10.1002\/hep4.1479","journal-title":"Hepatol Commun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez M","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017, 67:829-46. 10.1016\/j.jhep.2017.05.016","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016, 64:1388-402. 10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.021","article-title":"Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD","volume":"80","author":"Chen L","year":"2024","unstructured":"Chen L, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol. 2024, 80:e64-6. 10.1016\/j.jhep.2023.08.021","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2012.11.002","article-title":"Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis","volume":"52","author":"Musso G","year":"2013","unstructured":"Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013, 52:175-91. 10.1016\/j.plipres.2012.11.002","journal-title":"Prog Lipid Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2016.07.008","article-title":"Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis","volume":"1862","author":"Houben T","year":"2017","unstructured":"Houben T, Brandsma E, Walenbergh SM, Hofker MH, Shiri-Sverdlov R. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis. Biochim Biophys Acta Mol Cell Biol Lipids. 2017, 1862:416-29. 10.1016\/j.bbalip.2016.07.008","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.595371","article-title":"Oxidative stress in non-alcoholic fatty liver disease. An updated mini review","volume":"8","author":"Delli Bovi AP","year":"2021","unstructured":"Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative stress in non-alcoholic fatty liver disease. An updated mini review. Front Med (Lausanne). 2021, 8:595371. 10.3389\/fmed.2021.595371","journal-title":"Front Med (Lausanne)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/livers5010004","article-title":"Applicability of statins in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"5","author":"Prasoppokakorn T","year":"2025","unstructured":"Prasoppokakorn T. Applicability of statins in metabolic dysfunction-associated steatotic liver disease (MASLD). Livers. 2025, 5:4. 10.3390\/livers5010004","journal-title":"Livers"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105484","article-title":"Epigenetics in NAFLD\/NASH: targets and therapy","volume":"167","author":"Sodum N","year":"2021","unstructured":"Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD\/NASH: targets and therapy. Pharmacol Res. 2021, 167:105484. 10.1016\/j.phrs.2021.105484","journal-title":"Pharmacol Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4648","article-title":"Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline","volume":"173","author":"O'Malley PG","year":"2020","unstructured":"O'Malley PG, Arnold MJ, Kelley C, et al.. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2020, 173:822-9. 10.7326\/M20-4648","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.163106","article-title":"Pleiotropic effects of statins","volume":"19","author":"Kavalipati N","year":"2015","unstructured":"Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Indian J Endocrinol Metab. 2015, 19:554-62. 10.4103\/2230-8210.163106","journal-title":"Indian J Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26082323","article-title":"Paraoxonase 1 and non-alcoholic fatty liver disease: a meta-analysis","volume":"26","author":"Kotani K","year":"2021","unstructured":"Kotani K, Watanabe J, Miura K, Gugliucci A. Paraoxonase 1 and non-alcoholic fatty liver disease: a meta-analysis. Molecules. 2021, 26:2323. 10.3390\/molecules26082323","journal-title":"Molecules"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i7.1712","article-title":"Clinical approaches to non-alcoholic fatty liver disease","volume":"20","author":"Schwenger KJ","year":"2014","unstructured":"Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014, 20:1712-23. 10.3748\/wjg.v20.i7.1712","journal-title":"World J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249646","article-title":"Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: current issues and future perspectives in preclinical and clinical research","volume":"21","author":"Berardo C","year":"2020","unstructured":"Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: current issues and future perspectives in preclinical and clinical research. Int J Mol Sci. 2020, 21:9646. 10.3390\/ijms21249646","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404614-the-effect-of-statin-therapy-on-liver-enzymes-and-fibrosis-progression-in-patients-with-coexisting-cardiovascular-disease-and-non-alcoholic-fatty-liver-disease-nafld","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T18:52:06Z","timestamp":1756579926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404614-the-effect-of-statin-therapy-on-liver-enzymes-and-fibrosis-progression-in-patients-with-coexisting-cardiovascular-disease-and-non-alcoholic-fatty-liver-disease-nafld"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.91301","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,30]]}}}